Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

Monday, October 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health has announced the publication of the COSMOS-MEL01 study results in Cancer Research Communications. This study is significant as it is the first prospective, multicenter evaluation of the Guardant Reveal™ blood test, which is designed for detecting molecular residual disease and monitoring recurrence in melanoma patients. The findings support the test's utility in clinical settings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Publication in a reputable journal validates the study's findings.
  • The study demonstrates the effectiveness of the Guardant Reveal™ test.
  • It is the first prospective evaluation of a tissue-free blood test for MRD detection.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ blood test for molecular residual disease (MRD) detection and recurrence monitoring in patients wi

Frequently Asked Questions

What is the COSMOS-MEL01 study?

The COSMOS-MEL01 study is a prospective, multicenter evaluation of the Guardant Reveal™ blood test.

What does the Guardant Reveal™ test detect?

The Guardant Reveal™ test is designed to detect molecular residual disease and monitor recurrence in melanoma patients.

Where were the study results published?

The study results were published in Cancer Research Communications.

What is the significance of this study?

It is the first published evaluation of a tissue-free blood test for MRD detection in melanoma.

ShareAdd on Google
Tags: GH Guardant Health liquid biopsy melanoma molecular residual disease COSMOS study
Last updated: Oct 5, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~53 mo
Minimal dilution risk